Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: In a server device SV, component parts are recognized from an assembly drawing of a product included in design information sent from a product manufacturer (set manufacturer) to generate a parts list, further based on this parts list, the product manufacturer is requested to provide the contents of instruction required for manufacturing the component parts and specification information, and these are acquired to generate a manufacturing instruction. Furthermore, based on the generated manufacturing instruction, the component parts are classified into sets of ones that are the same or similar within a predetermined range in conditions of the material, the outer shape and dimensions, and the processing method to form order groups, and bidding matter information is disclosed on an order group-by-order group basis.

Abstract: To make parts order placement operations efficient to reduce a load on a product manufacturer regarding the parts order placement and to enable bidding opportunities of a parts manufacturer to increase and desired bidding matters to be selected simply and correctly. Generated bidding matter information is disclosed to a plurality of parts manufacturers, and when disclosing the aforementioned bidding matter information, a plurality of items of bidding matter information are edited as a data file for disclosure capable of undergoing sorting processing by each entry therein.

Abstract: In a manufacturing ordering assistance apparatus, there is received and stored each item of bidding information transmitted from a terminal of a parts manufacturer with respect to bidding item information, for each part, which is published in a browsable state, and it is set to a state where a product manufacturer can browse it only during a certain disclosure period. Then, when the product manufacturer selects the parts manufacturer as the order recipient among the items of bidding information, there is generated and presented information for confirming order reception and placement conditions to the product manufacturer and the parts manufacturer, and when both manufacturers agrees, there is generated order form information to report the order form information along with manufacturing instruction information separately generated to the parts manufacturer as the order recipient.

Abstract: The manufacturing ordering assistance apparatus, method and program according to the first embodiment of the present embodiment are configured such that the manufacturing ordering assistance apparatus capable of transmitting data by way of a network between a first terminal used by a product manufacturer and second terminals used by parts manufacturers acquires design information of a product from the first terminal; identifies information relating to parts from the acquired design information; generates, for the respective parts, parts manufacturing information necessary to manufacture the parts based on the identified information relating to the parts; and selects a parts manufacturer as an order recipient for the respective parts based on the generated parts manufacturing information and information relating to manufacturing capacities of the parts manufacturers.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: Provided is an Fe—Ni—Cr alloy that has excellent surface characteristics and enables formation of a blackened coating having excellent blackening characteristics and peeling resistance. The Fe—Ni—Cr alloy has a chemical composition containing, by mass %, C, Si, Mn, P, S, Cr, Ni, Mo, Co, Cu, N, Ti, Al, O, and H, the balance being Fe and inevitable impurities, and satisfying formulae (1) to (4): (1) T1=11×[% N]+0.1; (2) T2=?39×[% N]?1.0; (3) A1=7.5×[% N]+0.1; (4) A2=?42.5×[% N]+1.0, where [% M] represents content (mass %) of element M in the alloy, and T1, T2, A1, and A2 satisfy relationships T1<[% Ti]<T2 and A1<[% A1]<A2.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: Provided is an Fe—Ni—Cr alloy that has excellent surface characteristics and enables formation of a blackened coating having excellent blackening characteristics and peeling resistance. The Fe—Ni—Cr alloy has a chemical composition containing, by mass %, C, Si, Mn, P, S, Cr, Ni, Mo, Co, Cu, N, Ti, Al, O, and H, the balance being Fe and inevitable impurities, and satisfying formulae (1) to (4): (1) T1=11×[% N]+0.1; (2) T2=?39×[% N]?1.0; (3) A1=7.5×[% N]+0.1; (4) A2=?42.5×[% N]+1.0, where [% M] represents content (mass %) of element M in the alloy, and T1, T2, A1, and A2 satisfy relationships T1<[% Ti]<T2 and A1<[% A1]<A2.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: An austenitic Fe—Ni—Cr alloy comprises C: 0.005˜0.03 mass %, Si: 0.17˜1.0 mass %, Mn: not more than 2.0 mass %, P: not more than 0.030 mass %, S: not more than 0.0015 mass %, Cr: 18˜28 mass %, Ni: 21.5˜32 mass %, Mo: 0.10˜2.8 mass %, Co: 0.05˜2.0 mass %, Cu: less than 0.25 mass %, N: not more than 0.018 mass %, Al: 0.10˜1.0 mass %, Ti: 0.10˜1.0 mass %, Zr: 0.01˜0.5 mass %, and the balance being Fe and inevitable impurities; wherein Cr, Mo, N and Cu satisfy PRE=Cr+3.3×Mo+16×N?20.0 and PREH=411-13.2×Cr-5.8×Mo+0.1×Mo2+1.2×Cu?145.0 and wherein Al, Ti, and Zr satisfy 0.5?Al+Ti+1.5×Zr?1.5, and has an excellent corrosion resistance in air or under a wet environment even at a surface state having an oxide film formed by an intermediate heat treatment.

Abstract: High-Mn austenitic stainless steels having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.0028 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass % with the balance being Fe and inevitable impurities, provided that these components are contained so that ? cal represented by the following equation is not more than 5.5%: ? cal (mass %)=(Cr+0.48Si)?(Ni+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7, wherein each element symbol in the equation is a content of the respective element (mass %), and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: An austenitic Fe—Ni—Cr alloy comprises C: 0.005˜0.03 mass %, Si: 0.17˜4.0 mass %, Mn: not more than 2.0 mass %, P: not more than 0.030 mass %, S: not more than 0.0015 mass %, Cr: 18˜28 mass %, Ni: 21.5˜32 mass %, Mo: 0.10˜2.8 mass %, Co: 0.05˜2.0 mass %, Cu: less than 0.25 mass %, N: not more than 0.018 mass %, Al: 0.10˜4.0 mass %, Ti: 0.10˜1.0 mass %, Zr: 0.01˜0.5 mass %, and the balance being Fe and inevitable impurities; wherein Cr, Mo, N and Cu satisfy PRE=Cr+3.3×Mo+16×N?20.0 and PREH=411-13.2×Cr-5.8×Mo+0.1×Mo2+1.2×Cu?145.0 and wherein Al, Ti, and Zr satisfy 0.5?Al+Ti+1.5×Zr?1.5, and has an excellent corrosion resistance in air or under a wet environment even at a surface state having an oxide film formed by an intermediate heat treatment.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: High-Mn austenitic stainless steels having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.0028 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass % with the balance being Fe and inevitable impurities, provided that these components are contained so that ? cal represented by the following equation is not more than 5.5%: ? cal (mass %)=(Cr+0.48Si)?(Ni+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7, wherein each element symbol in the equation is a content of the respective element (mass %), and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: High-Mn austenitic stainless steels having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.0028 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass % with the balance being Fe and inevitable impurities, provided that these components are contained so that ? cal represented by the following equation is not more than 5.5%: ? cal (mass %)=(Cr+0.48Si)?(Ni+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7, wherein each element symbol in the equation is a content of the respective element (mass %), and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: As a stainless steel for a metal part for clothing ornament capable of working into a complicated form part and having such nonmagnetic properties that the worked part can cope with the detection through needle detecting device is provided a high-Mn austenitic stainless steel having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.03 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass %, provided that these components are contained so that ? cal (mass %) represented by the following equation (1) is not more than 5.5 mass %: ? cal (mass %)=(Cr+0.48Si+1.21Mo+2.2(V+Ti)+0.15Nb)?(Ni+0.47Cu+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7??(1) and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: An austenitic Fe—Ni—Cr alloy comprises C: 0.005˜0.03 mass %, Si: 0.15˜1.0 mass %, Mn: not more than 2.0 mass %, P: not more than 0.030 mass %, S: not more than 0.002 mass %, Cr: 18˜28 mass %, Ni: 20˜38 mass %, Mo: 0.10˜3 mass %, Co: 0.05˜2.0 mass %, Cu: less than 0.25 mass %, N: not more than 0.02 mass %, provided that PRE=Cr+3.3×Mo+16×N?20.0 and PREH=411?13.2×Cr?5.8×Mo+0.1×Mo2+1.2×Cu?145.0 (wherein each element symbol represents a content (mass %) of each element) and has an excellent corrosion resistance in air or under a wet environment even at a surface state having an oxide film formed by a intermediate heat treatment on the way of the production process.